StreetInsider.com News Articles

Enovis Corp (ENOV) PT Lowered to $34 at Needham

Mon, 12 Oct 2026 05:37:15 -0400

Needham analyst Mike Matson lowered the price target on Enovis Corp (NYSE: ENOV) to $34.00 (from $52.00) while maintaining a Buy rating.

The analyst comments "ENOV expects to close its acquisition of eCential Robotics (see here) by the end of 2026. ENOV expects the acquisition to reduce its adjusted EBITDA margin by ~150 bps in 2027, partially offset by ~50 bps of underlying improvement resulting in a net reduction of ~100 bps. ENOV also guided to 50 bps of adjusted EBITDA improvement in 2028. We have updated our model to reflect the dilution from the deal. We maintain our 2026E and

Enovis Corp (ENOV) PT Lowered to $34 at Needham

Mon, 12 Oct 2026 05:37:15 -0400

Needham analyst Mike Matson lowered the price target on Enovis Corp (NYSE: ENOV) to $34.00 (from $52.00) while maintaining a Buy rating.

Enovis to Host Third Quarter 2026 Results Conference Call on November 5th

Thu, 08 Oct 2026 08:00:00 -0400

Dallas, TX, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its third quarter 2026 financial results on Thursday, November 5th, 2026 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. The live webcast and a presentation related to the call will be accessible from the "Investors" section of Enovis' website at www.enovis.com.

Conference Call/Webcast Information

Investors can access the live webcast via

Enovis to Host Third Quarter 2026 Results Conference Call on November 5th

Thu, 08 Oct 2026 08:00:00 -0400

Conference Call/Webcast Information

Investors can access the live webcast via

Enovis Corp (ENOV) PT Lowered to $44 at UBS

Mon, 05 Oct 2026 09:33:34 -0400

(Updated - October 5, 2026 9:33 AM EDT)

UBS analyst Patrick Wood lowered the price target on Enovis Corp (NYSE: ENOV) to $44.00 (from $51.00) while maintaining a Buy rating.

The analyst commented, "We are updating our estimates to reflect impacts from ENOV's recent acquisition of eCential Robotics and broader seasonality dynamics. Management anticipates ~150 bps of deal related dilution to 2027 adj. EBITDA margins, offset by ~50 bps of underlying business improvement which brings total impact in '27 to ~100 bps headwind. The company expects margin to return to y/y improvement in 2028...Our $44 PT (prev. $51) is derived by applying

Enovis Corp (ENOV) PT Lowered to $44 at UBS

Mon, 05 Oct 2026 09:33:34 -0400

(Updated - October 5, 2026 9:33 AM EDT)

UBS analyst Patrick Wood lowered the price target on Enovis Corp (NYSE: ENOV) to $44.00 (from $51.00) while maintaining a Buy rating.

Form 4 Enovis CORP For: Sep 30 Filed by: Ortiz Christine

Thu, 01 Oct 2026 21:00:00 -0400

si-local-file:///var/storage/secattach/20261001/27137744.html

Nyxoah Appoints Liam Kelly as Chief Executive Officer

Mon, 28 Sep 2026 16:30:00 -0400

REGULATED INFORMATION
INSIDE INFORMATION

Nyxoah Appoints Liam Kelly as Chief Executive Officer

Further strengthening the Company’s strategic U.S. presence and focus

Mont-Saint-Guibert, Belgium – September 28, 2026, 10:30 pm CET / 4:30 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the appointment of Liam Kelly as Chief Executive Officer, effective October 1, 2026, succeeding Olivier Taelman.

The appointment reflects Nyxoah’s continued evolution into a U.S.-focused commercial organization following FDA

Nyxoah Appoints Liam Kelly as Chief Executive Officer

Mon, 28 Sep 2026 16:30:00 -0400

REGULATED INFORMATION
INSIDE INFORMATION

Nyxoah Appoints Liam Kelly as Chief Executive Officer

Further strengthening the Company’s strategic U.S. presence and focus

The appointment reflects Nyxoah’s continued evolution into a U.S.-focused commercial organization following FDA

Nyxoah Appoints Liam Kelly as Chief Executive Officer

Mon, 28 Sep 2026 16:30:00 -0400

REGULATED INFORMATION
INSIDE INFORMATION

Nyxoah Appoints Liam Kelly as Chief Executive Officer

Further strengthening the Company’s strategic U.S. presence and focus

The appointment reflects Nyxoah’s continued evolution into a U.S.-focused commercial organization following FDA

Nyxoah Appoints Liam Kelly as Chief Executive Officer

Mon, 28 Sep 2026 16:30:00 -0400

REGULATED INFORMATION
INSIDE INFORMATION

Nyxoah Appoints Liam Kelly as Chief Executive Officer

Further strengthening the Company’s strategic U.S. presence and focus

The appointment reflects Nyxoah’s continued evolution into a U.S.-focused commercial organization following FDA

Nyxoah Appoints Liam Kelly as Chief Executive Officer

Mon, 28 Sep 2026 16:30:00 -0400

REGULATED INFORMATION
INSIDE INFORMATION

Nyxoah Appoints Liam Kelly as Chief Executive Officer

Further strengthening the Company’s strategic U.S. presence and focus

The appointment reflects Nyxoah’s continued evolution into a U.S.-focused commercial organization following FDA

Nyxoah Appoints Liam Kelly as Chief Executive Officer

Mon, 28 Sep 2026 16:30:00 -0400

REGULATED INFORMATION
INSIDE INFORMATION

Nyxoah Appoints Liam Kelly as Chief Executive Officer

Further strengthening the Company’s strategic U.S. presence and focus

The appointment reflects Nyxoah’s continued evolution into a U.S.-focused commercial organization following FDA

Enovis becomes first multi-registry industry sponsor of AAOS Registry Program

Tue, 22 Sep 2026 12:02:00 -0400

Company expands its support from the American Joint Replacement Registry to include the Shoulder & Elbow Registry

ROSEMONT, Ill., Sept. 22, 2026 /PRNewswire/ -- The American Academy of Orthopaedic Surgeons (AAOS) announced that Enovis^™ has expanded its support of the AAOS Registry Program, becoming the first industry partner to sponsor multiple AAOS registries.

Enovis becomes first multi-registry industry sponsor of AAOS Registry Program

Tue, 22 Sep 2026 12:02:00 -0400

Company expands its support from the American Joint Replacement Registry to include the Shoulder & Elbow Registry

Form 4 Enovis CORP For: Sep 02 Filed by: Engert Oliver

Fri, 11 Sep 2026 11:35:00 -0400

si-local-file:///var/storage/secattach/20260911/27051790.html

Form 4 Enovis CORP For: Sep 04 Filed by: McDonald Damien

Fri, 11 Sep 2026 11:35:00 -0400

si-local-file:///var/storage/secattach/20260911/27051798.html

Form 4 Enovis CORP For: Sep 04 Filed by: Engert Oliver

Tue, 08 Sep 2026 21:00:00 -0400

si-local-file:///var/storage/secattach/20260908/27037949.html

Form 4 Enovis CORP For: Sep 02 Filed by: Engert Oliver

Fri, 04 Sep 2026 21:00:00 -0400

si-local-file:///var/storage/secattach/20260904/27030968.html

Form 4 Enovis CORP For: Sep 04 Filed by: McDonald Damien

Fri, 04 Sep 2026 21:00:00 -0400

si-local-file:///var/storage/secattach/20260904/27030967.html

Enovis Corp (ENOV) PT Lowered to $27 at BMO Capital

Wed, 02 Sep 2026 09:24:44 -0400

(Updated - September 2, 2026 9:24 AM EDT)

BMO Capital analyst Vik Chopra lowered the price target on Enovis Corp (NYSE: ENOV) to $27.00 (from $30.00) while maintaining a Outperform rating.

The analyst commented: "Margin Headwind, Strategic Tailwind; eCential Strengthens Long-Term Story; We view Enovis’ proposed acquisition of eCential Robotics as a strategically important, but financially back-end-loaded investment that fills the largest remaining gap in the company’s enabling technology portfolio. Enovis expects a net ~100 bps year-overyear margin headwind in 2027 and leverage is expected to increase to ~3.5x at closing before returning to ~3.0x by the end of 2027. We think

Enovis Corp (ENOV) PT Lowered to $27 at BMO Capital

Wed, 02 Sep 2026 09:24:44 -0400

(Updated - September 2, 2026 9:24 AM EDT)

BMO Capital analyst Vik Chopra lowered the price target on Enovis Corp (NYSE: ENOV) to $27.00 (from $30.00) while maintaining a Outperform rating.

Enovis Corp (ENOV) PT Lowered to $24 at JPMorgan

Wed, 02 Sep 2026 09:22:45 -0400

JPMorgan analyst Robbie Marcus lowered the price target on Enovis Corp (NYSE: ENOV) to $24.00 (from $28.00) while maintaining a Neutral rating.

Enovis Corp (ENOV) PT Lowered to $33 at Wells Fargo

Wed, 02 Sep 2026 07:28:06 -0400

Wells Fargo analyst Larry Biegelsen lowered the price target on Enovis Corp (NYSE: ENOV) to $33.00 (from $39.00) while maintaining a Overweight rating.

Enovis Corp (ENOV) PT Lowered to $47 at Citizens as eCential Robotics Acquisition Announced

Wed, 02 Sep 2026 04:13:12 -0400

Citizens analyst David Turkaly lowered the price target on Enovis Corp (NYSE: ENOV) to $47.00 (from $55.00) while maintaining a Market Outperform rating.

The analyst commented, "We reiterate our Market Outperform rating though lower our price target to $47 from $55 on shares of Enovis after the company announced its acquisition of eCential Robotics, a French developer of surgical robotics and enabling tech offerings, for ~€176 mln (~$205 mln, ~€155 mln EV; with up to €35 mln of contingent milestone payments). The transaction is expected to be funded by a combination of cash on hand and credit revolver capacity (which stood